



SUPRIYA LIFESCIENCE LIMITED
AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2024
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Part I - Statement of Standalone Audited Financial Results for the Quarter & Year Ended 31st March ,2024

(₹ In million)

Sr.No.	Particulars	Quarter ended 31-03-2024 Audited	Quarter ended 31-12-2023 Unaudited	Quarter ended 31-03-2023 Audited	Year ended 31-03-2024 Audited	Year ended 31-03-2023 Audited
	Income					
I	Revenue from Operations	1,581.80	1,400.74	1,422.70	5,703.70	4,609.38
II	Other Income	21.85	30.65	19.64	106.35	94.89
III	Total Income	1,603.66	1,431.39	1,442.35	5,810.05	4,704.27
2	Expenses					
	a) Cost of Materials Consumed	483.56	448.43	475.20	1,914.30	1,873.18
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods , work in progress & stock in trade.	99.05	97.78	0.39	303.11	(65.06)
	d. Employee benefit expenses	171.44	175.64	153.01	676.38	555.78
	e. Finance Cost	6.01	4.94	7.14	21.10	30.84
	f. Depreciation & amortisation expense	39.14	39.60	30.07	158.11	118.15
	g. Other expenditure	272.71	264.00	243.65	1,080.15	956.49
IV	Total Expenses	1,071.90	1,030.39	909.46	4,153.15	3,469.40
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	531.75	400.99	532.89	1,656.90	1,234.87
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	531.75	400.99	532.89	1,656.90	1,234.87
VIII	Tax Expense					
	a) Current Tax	89.44	96.55	132.07	371.00	306.81
	b) Deferred Tax	72.99	6.57	18.53	94.76	29.49
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	369.32	297.87	382.29	1,191.14	898.57
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	369.32	297.87	382.29	1,191.14	898.57
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	0.45	3.61	(6.22)	21.69	(16.80)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.11)	(0.91)	1.56	(5.46)	4.23
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	369.66	300.57	377.63	1,207.37	886.00
XVI	Earnings per equity Share (for continuing operation):					
	(1) Basic (In ₹)	4.59	3.77	4.75	14.80	11.15
	(2) Diluted (In ₹)	4.59	3.77	4.75	14.80	11.15
XVII	Earnings per equity Share (for discontinued operation):					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):					
	(1) Basic (In ₹)	4.59	3.77	4.75	14.80	11.15
	(2) Diluted (In ₹)	4.59	3.77	4.75	14.80	11.15




See accompanying notes to the financial statements:

Notes:-

1. The Audited Standalone financial results of the Company for the quarter & year ended March 31, 2024 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above Audited standalone financial results of the Company for the quarter & year ended March 31, 2024 have been reviewed by the Audit Committee on 28th May, 2024 and thereafter approved by the Board of Directors at their meeting held on 28th May, 2024.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
5. The standalone annual financial results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
6. The Board of Directors at their meeting dated 28th May,2024 have recommended final dividend of INR 0.80/- per equity share of INR 2/- each.

For and on behalf of The Board of directors of
Supriya Lifescience Limited


Dr. Satis Waman Wagh
Chairman & Managing Director
DIN: 01456982

PLACE :- MUMBAI
DATE :- 28.05.2024



Supriya Lifescience Ltd
CIN No: L51900MH2008PLC180452
Standalone Balance Sheet as at March 31, 2024
(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	Notes	Mar 31, 2024	March 31,2023
ASSETS			
Non-current assets			
(i) Property, plant and equipment	3	3,036.97	2,551.17
(ii) Right to Use Asset	3	47.79	53.15
(iii)Capital Work in progress	5	1,488.25	676.28
(iv) Intangible Assets	4	16.56	11.06
(v) Financial Assets			
-Investments	6	637.95	252.96
-Loans and Advances	7	-	-
(vi) Other Non- Current Assets	8	6.81	9.28
Total Non-current assets		5,234.33	3,553.90
Current assets			
(i) Inventories	9	852.49	1,157.70
(ii) Financial Assets			
-Loans and Advances	7	6.85	5.49
-Trade receivables	10	1,116.83	846.64
-Cash and cash equivalents	11(a)	683.49	852.51
-Bank balances other than (iii) above	11(a)	66.07	723.31
-Other Financial Assets	11(b)	45.09	64.06
(iii) Other current assets	12	1,207.22	999.16
Total Current Assets		3,978.04	4,648.87
TOTAL ASSETS		9,212.38	8,202.77
EQUITY AND LIABILITIES			
EQUITY			
(i) Equity share capital	13	160.97	160.97
(ii) Other equity	14	7,992.70	6,833.62
Total Equity		8,153.67	6,994.58
LIABILITIES			
Non-current liabilities			
(i) Financial Liabilities			
-Borrowings	15	-	-
-Lease Liabilities	16	50.20	54.89
-Other financial liabilities	17	-	-
(ii) Provisions	18	8.04	58.75
(iii) Deferred tax Liabilities	20	231.52	136.75
Total Non-Current Liabilities		289.76	250.39
Current liabilities			
(i) Financial liabilities			
-Borrowings	15	-	166.25
-Lease Liabilities	16	4.68	3.54
-Trade payables	19	-	-
Micro Enterprises and Small Enterprises Other than micro and small enterprises		595.69	642.28
-Other financial liabilities	17	15.74	8.21
(ii) Provisions	18	3.65	8.37
(iii) Other current liabilities	21	149.18	129.16
Total Current Liabilities		768.94	957.80
TOTAL EQUITY AND LIABILITIES		9,212.38	8,202.77

Summary of significant accounting policies

2

For and on behalf of the Board of Directors of
SUPRIYA LIFESCIENCE LIMITED

Dr. Satish Waman Wagh
Chairman & Managing
Director
DIN : 01456982



Place: Mumbai
Date: 28.5.2024



Supriya Lifescience Ltd
CIN No: L51900MH2008PLC180452


Cash flow statement for the year ended March 31, 2024
(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	For the year ended Mar 31,2024	For the year ended March 31,2023
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	1,656.90	1,234.87
Adjustments for		
Depreciation and Amortization	158.11	118.15
Interest Income (Net of Expenses)	(100.24)	(89.95)
Dividend Received	(0.05)	(0.05)
Employee Benefit	(33.73)	16.88
Loss on Sale of fixed Assets	-	1.11
Modification of Lease	(0.05)	-
Other Non Cash Item		
Operating profit before working capital changes	1,680.94	1,281.00
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(270.19)	305.19
Inventories	305.21	(234.58)
Other Non Current & Current Assets	(205.01)	(413.27)
Other Non Current & Current Financial Assets	18.97	(3.73)
Loans and Advances	(1.36)	0.26
	(152.38)	(346.13)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	(46.59)	152.56
Other Non Current & Current Financial Liabilities	7.53	0.27
Other Non Current & Current liabilities	20.02	(144.85)
	(19.04)	7.98
(Income tax paid)/net of refund	(376.45)	(306.80)
Net Cash generated from Operating Activities	1,133.07	636.05
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(1,456.55)	(1,079.10)
(Purchase)/ Sale of Investments	(385.00)	(252.43)
Interest Income	105.75	94.94
Dividend Received	0.05	0.05
Net Cash generated/(outflow) from Investing Activities	(1,735.75)	(1,236.54)
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Shares	-	-
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	(166.25)	(46.70)
Finance Cost	(5.51)	(4.99)
Dividend Paid	(48.29)	(48.29)
Repayment of Lease liability	(3.54)	(2.78)
Net Cash generated from Financing Activities	(223.59)	(102.76)
Net Increase/(Decrease) in Cash and Cash equivalents	(826.26)	(703.26)
Cash and Cash Equivalents at the end of previous period	1,575.82	2,279.08
Cash and Cash Equivalents as at the end of the reporting period	749.56	1,575.82

For and on behalf of the Board of Directors of
Supriya Lifescience Limited


Dr. Satish Waman Wagh
Chairman &
Managing Director
DIN : 01456982

Place: Mumbai
Date: 28.05.2024



KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B. Com., B.L., F.C.A.

SUBHASH S. KOTADIA B. Com.(HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B. Com., F.C.A.

AMAR J. BHANUSHALI B. Com., D.T.M., F.C.A.

VINAYAK P. BAFANA B. Com., F.C.A.

DATE :

INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUPRIYA LIFESCIENCE LIMITED

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **SUPRIYA LIFESCIENCE LIMITED** ("the Company"), for the three months and year ended March 31, 2024 ("the Statement"/"Standalone Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financials statement:

- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2024.

Basis for Opinion

We conducted our audit of these Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical

"KAKARIA'S *Excellenza*"

Royal Fortune Complex, Daman Road, Chala, Vapi-396191

Phone : +91 9512004623 to 34. Email : ho@kakariaassociates.com, Website : www.kakariaassociates.com



responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim Condensed Standalone Financial Statements for the three months and year ended March 31, 2024. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial

Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of



assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 {3} (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



Vinayak P. Bafana
Partner

Membership No. – 159364

Place: - Vapi

Date: - 28th May, 2024

UDIN: - 24159364BKATBK7377

